Prior studies have revealed the immunotherapeutic properties of a vaccine prepared by transfer of genomic DNA from breast cancer cells into a highly immunogenic cell line. The rationale for this type of vaccine is that genes specifying an array of weakly immunogenic, unique tumor antigens associated with the malignant cells will be expressed in a highly immunogenic form by the transfected cells. Here, the immunotherapeutic properties of a vaccine prepared by transfection of mouse fibroblasts with DNA from a breast carcinoma (SB-5b) that arose spontaneously in a C3H/He mouse (H-2K b ) were tested in mice with intracerebral breast cancer. To augment their nonspecific immunogenic properties, before DNA transfer, the fibroblasts (of C3H/He mouse origin) were modified to express allogeneic MHC class I H-2K b -determinants and to secrete IL-2, IL-18 or GM-CSF. The results indicate that C3H/He mice injected intracerebrally (i.c.) with the breast cancer cells and syngeneic/allogeneic-transfected fibroblasts modified to secrete IL-2 survived significantly longer (Po.005) than mice in various control groups, including mice injected i.c. with the breast cancer cells alone. The immunotherapeutic properties of transfected fibroblasts modified to secrete IL-18 or GM-CSF were less efficacious. The results of two independent in vitro cytotoxicity assays indicate that systemic cellular antitumor immunity was generated in mice injected i.c. with the transfected cells, and the immunity was mediated predominantly by CD8 þ T cells.
I n most instances, proliferating neoplastic cells fail to provoke antitumor immune responses that are capable of controlling tumor growth. Unique tumor-associated antigens (TAAs) expressed by the neoplastic cells are insufficiently immunogenic. The successful induction of antitumor immune responses could lead to tumor cell destruction, prolonging the survival. This question is especially challenging for patients bearing intracerebral (i.c.) metastatic neoplasms. In particular, the survival of patients with i.c. breast cancer ranges from 8 to 13 months. 1, 2 Numerous reports indicate that the secretion of various cytokines by tumor cells augments their immunogenic properties. [3] [4] [5] The cytokine-secreting malignant cells are rejected by experimental animals, which are highly susceptible to the growth of the unmodified cells. The injection of mice with syngeneic tumor cells modified to secrete interleukin-2 (IL-2), 3 granulocyte-macrophage colony-stimulating factor (GM-CSF), 4, 5 interferon-a, [6] [7] [8] IL-4, 9 IL-12, 10 IL-18 11 and IL-23, 12 among others, resulted in antitumor immune responses that, in some instances, were capable of prolonging the lives of mice with established neoplasms. Since the antitumor immune responses were directed toward the neoplastic cells alone, nonmalignant cells were unaffected; it is likely that the immunity was directed toward unique T-cell determinants expressed by the malignant cells.
Tumor-associated T-cell epitopes are the products of mutant/dysregulated genes in the neoplastic cells that differ from the homologous genes in non-neoplastic cells of the tumor-bearing host. The products of genes specifying HER-2/neu in breast cancer, for example, were found to act as ''targets'' of immune-mediated attack. 13 The population of malignant cells taken as a whole consists of various subpopulations that express an array of TAAs most of which have not been identified.
Here, we compare the immunotherapeutic properties of a vaccine prepared by transfer of DNA from an adenocarcinoma of the breast that arose spontaneously in a C3H/He mouse. The vaccine cells were also modified to secrete IL-2, IL-18 or GM-CSF. The rationale was that mutant/dysregulated genes in the breast cancer cells specifying weakly immunogenic TAAs would be expressed in a highly immunogenic form by the transfected cells, and that cytokine-secretion by the vaccine will augment the cells' nonspecific immunogenic properties. Prior data in mice with breast neoplasms confirmed the validity of this approach.
14 In this study, the vaccine was evaluated in mice with i.c. breast cancer, as a model for common terminal events in breast cancer patients. The results indicate that mice injected i.c. with the breast cancer cells and DNA-transfected fibroblasts modified to secrete IL-2 survived significantly longer (Po.005) than mice in various control groups. Systemic T-cell-mediated immunity directed toward the breast cancer cells was induced in mice injected i.c. with the IL-2-secreting transfected cells.
Materials and methods

Cell lines and experimental animals
In all, 4-6-week-old pathogen-free C3H/He (H-2 k ) mice were obtained from Charles River Breeding Laboratories (Portage, MI). The mice were maintained in the animal care facilities of the University of Illinois, according to National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. They were 6-8 weeks old when used in the experiments. SB-5b cells were derived from an adenocarcinoma of the breast, which formed spontaneously in a C3H/He mouse in our animal colony. The SB-5b cells were grown by in vitro passage. LM cells, a fibroblast cell line of C3H/He mouse origin, were obtained from the American Type Culture Collection (Manassas, VA). All the cells were maintained at 371C in a humidified 7% CO 2 /air atmosphere in DMEM (Life Technologies, Grand Island, NY) supplemented with 10% FBS (Sigma, St Louis, MO) and antibiotics (Life Technologies) (growth medium).
Modification of fibroblasts to secrete IL-2, IL-18 or GM-CSF
To augment their nonspecific immunogenic properties, before transfection, the fibroblasts were modified to secrete IL-2, IL-18 or GM-CSF. IL-2-secreting fibroblasts (LM-IL-2 cells) were prepared as described previously. 15 In brief, a gene specifying human IL-2 (the biological properties of human IL-2 in mice are equivalent to that of mouse IL-2 15 ) was transduced into LM fibroblasts with the retroviral vector pZipNeoSVIL-2 (obtained originally from T Taniguchi, Institute for Molecular and Cellular Biology, Osaka University, Osaka, Japan). 16 The vector specified the human IL-2 gene and the neo r gene (confers resistance to the neomycin analog, G418). 17 Every third passage, the cells were placed in growth medium containing 300 mg/ml G418. Under these circumstances, the quantity of IL-2 secreted by the cells after 3 6 modified fibroblasts in 10 ml of DMEM, without FBS. For use as a control, an equivalent number of fibroblasts were transfected with 1 mg of pBabePuro alone. Afterward, the cells were incubated in DMEM for 18 hours at 371C in a CO 2 /air atmosphere, washed with DMEM, followed by the addition of growth medium. After incubation for 48 hours, the cell cultures were divided and replated in growth medium supplemented with 3.0 mg/ ml puromycin (Sigma; St Louis, MO) followed by incubation at 371C for 7 days. The surviving colonies were pooled and tested by immunofluorescent staining with specific FITC-conjugated antibodies for the expression of H-2K b -determinants. A total of 100% of nontransfected fibroblasts maintained in growth medium containing puromycin died during the 7-day period of incubation.
Immunofluorescent staining and cytofluorometric measurements
Quantitative immunofluorescence measurements were used to detect the presence of H- b -determinants (Pharmingen, San Diego, CA). After incubation, the cells were washed and analyzed by FACS. One-parameter fluorescence histograms were generated by analyzing at least 1 Â 10 4 cells in each instance. Background staining was determined by substituting cells incubated with FITC-conjugated mouse isotype-specific IgG2a serum alone for cells incubated with the specific FITC-conjugated antibodies.
Transfection of modified fibroblasts with sheared genomic DNA from a breast carcinoma that arose spontaneously in a C3H/He mouse (SB-5b)
Genomic DNA was isolated (Qiagen, Chatsworth, CA) from a mammary adenocarcinoma (SB-5b) that arose spontaneously in a C3H/He mouse. The genomic DNA was used to transfect the modified fibroblasts, using the method described by Wigler et al, 18 as modified. Briefly, high molecular weight DNA was sheared by three passages through a 25-gauge needle. The approximate size of the DNA at the time it was used in the experiments was 25 kb, as determined by agarose gel electrophoresis. Afterward, 100 mg of sheared DNA was mixed with 10 mg pCDNA6/V5-HisA, a plasmid which gives resistance to the antibiotic Blasticidin. The sheared tumor-DNA and plasmid-DNA (the DNA:plasmid ratio was 10:1 to ensure that cells that were converted to Basticidin-resistance took up DNA from the breast carcinoma cells as well) were then mixed with Lipofectamine 2000, according to the manufacturer's instructions (Life Technologies, Carlsbad, CA). The DNA/Lipofectamine mixture was added to a population of 1 Â 10 7 actively proliferating modified fibroblasts cells divided into 10 dishes containing 1 Â 10 6 cells. After 18 hours, the medium was replaced with fresh growth medium. The fibroblasts were maintained for 14 days in growth medium containing 2-5 mg/ml Blasticidin HCl (Invitrogen, Carlsbad, CA). In all, 100% of the cells transfected with tumor DNA alone maintained in the Basticidin growth medium died within this period. The surviving colonies (at least 2.5 Â 10 4 ) were pooled and maintained as a cell line for use in the experiments.
I.c. injection of C3H/He mice with SB-5b breast cancer cells
As a model of i.c. metastatic breast cancer in patients, C3H/He mice were injected intracerebrally (i.c.) with the breast cancer cells. Anesthetized mice were placed into a stereotactic frame. A 1 mm burr hole was introduced into the right frontal lobe in the region of the coronal suture using a D#60 drill bit (Plastics One, Roanoke, VA). A Hamilton syringe containing a 26 gauge needle with a small 2-3 mm piece of solder placed 3-4 mm from the tip of the needle to maintain a uniform depth of injection was used to introduce the breast cancer cells into the brain.
The total injection volume was 5-10 ml. After injection, the incision over the burr hole was closed with a single 5-O Dexon absorbable suture.
T-cell-mediated cytotoxicity toward breast cancer cells in mice immunized with the transfected fibroblasts
A CellTiter 96 aqueous nonradioactive cell proliferation assay kit (Promega, Madison, WI) was used to measure Tcell-mediated cytotoxicity toward the breast cancer cells in mice immunized with the transfected fibroblasts. Effector T cell (recovered from the spleens of immunized mice by Histopaque (Sigma) density gradient 19) and mitomycin Ctreated (50 mg/ml for 45 minutes) SB-5b target cells were cocultured at 371C for 18 hours at a 30:1 effector:target (E:T) cell ratio. Afterward, the nonadherent cells were removed, washed and viable SB-5b cells were added at various E:T ratios for 4 hours at 371C in a 7% CO 2 /air atmosphere. The number of remaining viable cells was measured by methylthiazolyl tetrazolium salt (MTS), which is bioreduced by viable cells into a formazan product that can be detected at 490 nm. Negative control wells were treated with 2% Triton-100 to cause total lysis of the cells. Positive control wells did not receive effector cells. Next, 20 ml of MTS and 1 ml of phenazine methosulfate (PMS), an electron coupling reagent, were mixed and added to each well, followed by incubation at 371C for 1-4 hours in a 7% CO 2 /air atmosphere after which the absorbance was read. The percent specific lysis was calculated from the absorbance using the formula as follows:
Experimental group À Negative control Positive control À Negative control Â100
ELISPOT IFN-g assays In some instances, mAbs for T-cell subsets or NK/LAK cells were added to the mixed cell cultures before the ELISPOT assays were performed as a means of identifying the cell types activated for antitumor immunity in the immunized mice, as described previously. 19 The spots were counted using computer-assisted image analysis (ImmunoSpot Series 2 analyzer: Cellular Technology Limited, Cleveland, OH).
Statistical analysis
Student's t-test was used to determine the statistical differences between the survival of mice in various Treatment of a brain tumor with transfected fibroblasts T Lichtor et al experimental and control groups. A P-value less than 0.05 was considered significant.
Results
Cytokine-secretion by LM mouse fibroblasts transduced with plasmid vectors specifying IL-2, IL-18 or GM-CSF, immune augmenting cytokines
To augment their nonspecific immunogenic properties, the fibroblasts used as recipients of DNA from the breast cancer cells were modified before DNA transfer to secrete IL-2, IL-18 or GM-CSF. Genes specifying the relevant cytokines were introduced into the cells by transduction with plasmid vectors. The vectors also specified a gene conferring resistance to an antibiotic, used for selection. An ELISA assay was used to measure cytokine secretion by the transduced fibroblasts. The results indicated that antibiotic-resistant cells transduced with pZipNeoSVIL-2 (specifies IL-2) formed 2214 pg IL-2/ml/10 6 cells/72 hours. Cells transduced with pMFG.puroIL-18 (specifies IL-18) formed 12.6 pg IL-18/ml/10 6 cells/72 hours and cells transduced with pMFG.puroGM-CSF (specifies GM-CSF) formed 2528 pg/ml GM-CSF/10 6 cells/72 hours. Cells transduced with the noncytokine specifying vector pMFGpuro did not form detectable amounts of the cytokines. Every third passage, the transduced fibroblasts were passaged in medium containing antibiotic. Under these circumstances, equivalent quantities of cytokine were present after 3 months of continuous culture. The generation time of transduced and nontransduced fibroblasts, approximately every 24 hours, was equivalent. . Allogeneic MHC-determinants are strong immune adjuvants. 20 To further augment their immunogenic properties, the cytokine-secreting fibroblasts used as DNA recipients were subsequently modified to express H-2K b -determinants. A plasmid, pBR327H-2K b , was used for this purpose. The results (Table 1) T-cell-mediated toxicity toward breast cancer in mice immunized with transfected fibroblasts modified to secrete IL-2, GM-CSF or IL-18
To determine if the immunity in mice injected i.c. with the transfected fibroblasts was local or systemic, spleen cells from mice injected i.c. with the transfected cells were analyzed for cytotoxic effects toward the breast cancer cells. An MTS-based cytotoxicity assay was used for this purpose. The analysis was performed 2 weeks after the i.c. injection of breast cancer cells and the transfected modified fibroblasts. The results (Fig 2) indicated that the spleen cell-mediated cytotoxic responses of greatest magnitude were in mice injected i.c. with breast cancer cells and transfected fibroblasts modified to secrete IL-2. Lesser cytotoxic effects were present in mice injected i.c. with SB-5b cells and transfected fibroblasts modified to secrete IL-18 or GM-CSF. Thus, systemic immune responses directed toward the breast cancer cells were induced in mice injected i.c. with the cytokine-secreting transfected cells and, like their effects on survival, cells modified to secrete IL-2 were most efficacious in this regard. Elispot-IFN-g assays were used as an additional means of determining if T cells directed toward the breast cancer Treatment of a brain tumor with transfected fibroblasts T Lichtor et al cells were present in the spleens of mice injected i.c. with the transfected cells. T cells were recovered by Hypaque density gradient centrifugation from the spleens of mice that survived for at least six weeks following the i.c. injection of the breast cancer cells and the transfected fibroblasts. The cells were coincubated with the breast cancer cells for 16 hours at 371C in wells before the nonadherent cells were transferred to the ELISPOT plates containing wells precoated with a high-affinity monoclonal antibody for INF-g. After further steps, the number of spots was determined by a computer-aided spot counter. The results indicated that the highest number of spots was present in spleen cells from surviving mice injected i.c. with breast cancer cells and fibroblasts modified to secrete IL-2 (Fig 3) . Lesser numbers of spots were found in T cells from mice injected with the breast cancer cells and nonsecreting transfected fibroblasts or breast cancer cells and transfected fibroblasts modified to secrete GM-CSF. The analysis of spleen cells from mice injected i.c. with SB-5b cells and transfected fibroblasts modified to secrete IL-18 could not be performed because none of these mice survived for 6 weeks.
The inhibitory effects of antibodies against various T-cell subsets were used to determine the types of cells activated for antitumor immunity in mice injected i.c. with the transfected fibroblasts. The assay was performed 2 weeks after the cells were first injected. As indicated (Fig 4) the greatest inhibitory effects were found in mixed cell cultures carried out in the presence of CD8 þ antibodies. Lesser inhibitory effects were observed in the presence of CD4 þ and NK/LAK antibodies.
Discussion
Antitumor immune responses were generated in C3H/He mice injected i.c. with a mixture of breast cancer cells and cytokine-secreting mouse fibroblasts transfected with unfractionated genomic DNA from the breast cancer cells. The immunity was sufficient to prolong survival, although the mice eventually died of the disease. A major advantage of this type of vaccine is that the fibroblasts could be genetically modified in advance of DNA transfer to augment their immunogenic properties. In this instance, the cells were modified to express allogeneic class I MHC-determinants (allogeneic MHC-determinants are strong immune adjuvants and ensure that the cells will be rejected) and to secrete one of three Th1 We made no effort to compare the benefits of fibroblasts modified to secrete various other immune augmenting cytokines. Conceivably, IL-2 is not most efficacious in this regard. Greater benefits might result if the cells used as DNA recipients were modified to secrete different cytokines, either singly or in combination. This report is an extension of a prior study in which the therapeutic benefits of transfected fibroblasts were investigated in C3H/He mice injected into the fat pad of the breast with a syngeneic breast cancer cells. 14 The results of this previous study indicated that the antitumor immunity was specific for breast cancer. The survival of the tumor-bearing mice was prolonged. Like most immunotherapy protocols, the mice were not cured of the disease. Other prior studies by this laboratory indicated that mice with an i.c. glioma, melanoma or breast carcinoma treated solely by intratumoral injections with allogeneic cells genetically modified to secrete IL-2 were found to survive significantly longer than mice in various control groups. 21, 22 The antitumor response was mediated predominantly by T-cell subsets (CD8 þ and NK/LAK cells). The immunizations appeared to be without toxicity. Mice injected i.c. with the cytokinesecreting allogeneic cells alone exhibited no neurologic deficit and survived their anticipated life spans.
The rationale for a vaccine prepared by transfer of genomic DNA from breast cancer cells into a highly immunogenic cell line is that undefined genetic events in 6 spleen cells is measured. The frequency of tumor-specific effector cells in the spleen before vaccination was 0.002%. The frequencies of tumorspecific effector cells in the spleen after vaccination with LMKb/SB5b, LMIL-2Kb/SB-5b, LMIL-18Kb/SB-5b and LMIL-2Kb/SB5b þ LMIL-18Kb/SB-5b are 0.02, 0.06, 0.02 and 0.07%, respectively. The over all P-value between unstimulated vs tumor cell stimulated group is 0.001. Significantly lowered (P ¼ .02*) IFN-g spots were found in LMIL-2Kb/SB-5b vaccinated, CD8 blocked group. The error bars represent one standard deviation.
Treatment of a brain tumor with transfected fibroblasts T Lichtor et al the malignant cells specify unique, undefined TAAs. The TAAs are weakly immunogenic and fail to provoke antitumor immune responses that are capable of controlling tumor growth. Under appropriate circumstances, however, such as expression by a highly immunogenic cell in the presence of a high local concentration of IL-2, the ''weak'' TAAs can stimulate an antitumor immune response.
The results presented here raise the possibility that a cytokine-secreting cell line can be prepared for subsequent modification to provide specificity for TAAs of an individual neoplasm. Although it is of obvious theoretical importance, the number of genes specifying such determinants and their precise characterization is not critical if the cells are to be used as a source of DNA for vaccine preparation.
Since the tumor cell population is known to be heterogeneous and includes cells that are resistant to cellular immune mechanisms, it is likely that a subpopulation of malignant breast cancer cells, resistant to host immune mechanisms, survived. For further control, a combination of therapeutic strategies will be required. Conceivably, intratumoral injection of a population of multiple cytokine-secreting, transfected cells, in combination with surgery and chemotherapy, will result in an enhanced response.
